Description

DEJAC-T TAB (1X4)

Indications

DEJAC-T TAB is primarily indicated for the management of various conditions associated with pain and inflammation. It is commonly prescribed for patients suffering from acute and chronic pain, including but not limited to osteoarthritis, rheumatoid arthritis, and other musculoskeletal disorders. Additionally, DEJAC-T TAB may be used in the treatment of fever and as an adjunct therapy in post-operative pain management.

Mechanism of Action

The active ingredients in DEJAC-T TAB work synergistically to alleviate pain and reduce inflammation. The formulation typically includes a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, which are crucial for the synthesis of prostaglandins. By reducing the production of these inflammatory mediators, DEJAC-T TAB effectively diminishes pain and swelling. The analgesic properties of the medication also contribute to its efficacy in managing discomfort associated with various medical conditions.

Pharmacological Properties

DEJAC-T TAB exhibits several pharmacological properties that enhance its therapeutic effectiveness. The NSAID component provides anti-inflammatory, analgesic, and antipyretic effects. The pharmacokinetics of DEJAC-T TAB demonstrate rapid absorption following oral administration, with peak plasma concentrations typically achieved within one to two hours. The drug is metabolized in the liver and excreted primarily through the kidneys. The half-life of the active substances allows for convenient dosing schedules, ensuring sustained relief from symptoms.

Contraindications

DEJAC-T TAB is contraindicated in patients with a known hypersensitivity to any of its components. It should not be used in individuals with active gastrointestinal bleeding, peptic ulcer disease, or severe renal impairment. Patients with a history of cardiovascular diseases, particularly those who have experienced myocardial infarction or stroke, should use this medication with caution. Additionally, DEJAC-T TAB is not recommended for use during pregnancy, particularly in the third trimester, due to potential risks to the fetus.

Side Effects

While DEJAC-T TAB is generally well-tolerated, some patients may experience side effects. Common adverse reactions include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. More serious side effects can occur, including gastrointestinal bleeding, renal impairment, and allergic reactions. Patients should be advised to report any unusual symptoms or severe side effects to their healthcare provider promptly. Monitoring for signs of liver dysfunction is also recommended, especially in long-term use cases.

Dosage and Administration

The recommended dosage of DEJAC-T TAB may vary based on the individual patient’s condition and response to treatment. For adults, the typical starting dose is one tablet taken orally every 8 to 12 hours as needed for pain relief. It is important not to exceed the maximum recommended daily dose to minimize the risk of adverse effects. For pediatric patients, the dosage should be determined by a healthcare professional based on the child’s weight and clinical condition. DEJAC-T TAB should be taken with food or milk to reduce gastrointestinal irritation.

Interactions

DEJAC-T TAB may interact with other medications, potentially altering their effects or increasing the risk of side effects. Co-administration with other NSAIDs or anticoagulants can heighten the risk of gastrointestinal bleeding. Additionally, the use of DEJAC-T TAB with certain antihypertensive medications may reduce their effectiveness. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions. Regular monitoring may be required for those on multiple medications.

Precautions

Patients taking DEJAC-T TAB should be monitored for signs of gastrointestinal bleeding, especially those with a history of ulcers or gastrointestinal disorders. Caution is also advised in patients with pre-existing liver or kidney conditions, as the medication may exacerbate these issues. It is essential to evaluate the risk-benefit ratio in patients with cardiovascular diseases, as NSAIDs can increase the risk of thrombotic events. Pregnant and breastfeeding women should consult their healthcare provider before using DEJAC-T TAB to ensure safety for both mother and child.

Clinical Studies

Clinical studies have demonstrated the efficacy of DEJAC-T TAB in managing pain and inflammation in various populations. Research indicates significant reductions in pain scores and improvements in functional outcomes among patients with osteoarthritis and rheumatoid arthritis. In a randomized controlled trial, patients taking DEJAC-T TAB reported enhanced quality of life and decreased reliance on additional analgesics. Long-term studies have also suggested that DEJAC-T TAB maintains its efficacy over extended periods, with manageable side effects when used as directed.

Conclusion

DEJAC-T TAB is a valuable therapeutic option for the management of pain and inflammation in various clinical settings. Its well-established mechanism of action, along with its pharmacological properties, makes it an effective choice for patients suffering from acute and chronic pain conditions. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure safe and effective use. Patients should engage in open communication with their healthcare providers to optimize their treatment plan and address any concerns regarding the use of DEJAC-T TAB.